Your Position: Home > Journal List > China Medicine > Paper

Analysis of the efficacy of initially antiviral therapy for chronic hepatitis B

( views:131, downloads:0 )
Author:
LI Chao-qun(Department of Infectious Diseases, Shaoyang Central Hospital, Hunan Province,Shaoyang 422000 ,China)
TANG Li-mei(Department of Infectious Diseases, Shaoyang Central Hospital, Hunan Province,Shaoyang 422000 ,China)
Journal Title:
China Medicine
Issue:
Volume 07, Issue 07, 2012
DOI:
10.3760/cma.j.issn.1673-4777.2012.07.021
Key Word:
Hepatitis B, chronic;Antiviral agents;Entecavir;Lamivudine

Abstract: Objective To compare the efficacy of initially antiviral therapy for chronic hepatitis B with home-made Entecavir dispersible tablets and imported enteeavir tablets and lamivudine.Metbods Totally 168HBeAg-positive patients without receiving any antiviral therapy were selected.Patients were randomly divided into 3 groups:lamivudine group(58 cases),imported entecavir tablets(56 cases) and home-made entecavir dispersible tablets(54 cases),respectively,for 1 year.Results The serum ALT normalization rate,HBeAg negative rate and the HBV DNA negative rate of home-made Entecavir dispersible tablets group in the 12th,24th and 48th week were significantly higher than those of lamivudine group.In the 12th,24th and 48th week ALT normalization,HBeAg and HBV DNA negative conversion rate of home-made entecavir was significantly higher than those of the lamivudine group.There was no significant difference between imported entecavir group and home-made entecavir group.Conclusion Home-made entecavir for the treatment of chronic hepatitis initial antiviral efficacy is significantly higher than lamivudine group but there is no significant difference with imported entecavir.

  • [1]中华医学会肝病分会,中华医学会感染病分会.慢性乙型肝炎防治指南(2010年版).中华内科杂志,2011,50(2):169-179.
  • [2]Fattovich G,Giustina SW,Schalm SW,et al.Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B.The EUROHEP study Group on Hepatitis B Virus and Cirrhosis.Hepatology,1995,21(1):77-82.
  • [3]于乐成,万谟彬,陈成伟.美国肝病学会慢性乙型肝炎实践指南(2007年)精要.肝脏.2007,12(S1):58-77.
  • [4]杨绍基,任红,李兰娟,等.传染病学.7版.北京:人民卫生出版社,2008:45,47.
  • [5]姚光弼,王宝恩,崔振宇,等.拉米夫定治疗慢性乙型肝炎三年疗效观察.中华内科杂志,2003,42(6):382-387.
  • [6]李纯平,邓丽宁,侯宏波,等.恩替卡韦治疗乙型肝炎肝硬化的疗效观察.疑难病杂志,2011,10(3):211-212.
  • [7]韩晋,易毛,吴荣荣,等.恩替卡韦分散片的处方工艺研究.中国药学杂志,2009,44(22):1718-1722.
  • [8]盛秋菊,丁洋,窦晓光.恩替卡韦治疗慢性乙型肝炎疗效的早期分层评价.实用药物与临床,2010,13(3):167-171.
  • [9]侯春阳,李方治.恩替卡韦对慢性乙型肝炎抗病毒治疗的临床分析.实用药物与临床,2008,11(1):9-11.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn